IMGN News and Press, ImmunoGen Inc. From 10/12/20

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it has raised gross proceeds of approximately $54.8 million through its At-the-Market (“ATM") facility pursuant to its Open Market ...

Looking For Penny Stocks To Buy Now? There’s no doubt that the stock market today is feeling excited and penny stocks are joining the party. As we noted last night, there’s been a clear indication that larger-cap stocks are seeing lighter volume. Indicated by compa...

Are These Pre Market Penny Stocks On Your Watch List? Are you looking for the best penny stocks to buy now? I’m sure you and hundreds of other traders are scouring through stock charts and looking at scanners to pick up on the next big momentum move in the stock market to...

MyoKardia (MYOK) +59% as Bristol to acquire the company for $225/Share.Kosmos Energy (KOS) +50% as company closed a Gulf of Mexico facility with Beal Bank USA and Trafigura Trading LLC.Enlivex Therapeutics (ENLV) +49%.Corvus Pharmaceuticals (CRVS) +38% on co-foun...

The FDA designates ImmunoGen's (IMGN) IMGN632 a Breakthrough Therapy for the treatment of patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive type of blood cancer that can involve the bone marrow and is typically characterized by deep purple s...

ImmunoGen, Inc. , (Nasdaq: IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for IMGN632 for the treatment of patients wi...

Gainers: [[JAX]] +4.5%. [[AXGT]] +4.4%. [[HRI]] +3.1%. [[AVDL]] +2.3%. [[AAL]] +1.7%.Losers: [[TATT]] -6.2%. [[FNKO]] -3.5%. [[IMGN]] -3.0%. [[VIVO]] -2.6%. [[INMD]] -1.6%. For further details see: AXGT, AVDL, INMD and IMGN among after-hours movers

Sorrento Therapeutics (NASDAQ: SRNE )   +30%  on FDA nod for early-stage COVID-19 antibody trial. More news on: Sorrento Therapeutics, Inc., Hepion Pharmaceuticals, Inc., Vaccinex, Inc., , Stocks on the move, Read more ...

ImmunoGen (NASDAQ: IMGN ) announces final data from the FORWARD II triplet cohort evaluating mirvetuximab soravtansine in combination with carboplatin and Avastin (bevacizumab) in patients with folate receptor alpha (FRα)-positive recurrent, platinum-sensitive ovarian cancer at th...

Triplet Combination Demonstrates Encouraging Anti-Tumor Activity and Tolerability in Recurrent Platinum-Sensitive Ovarian Cancer ImmunoGen, Inc. , (Nasdaq: IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final data ...